TABLE 1.
Baseline characteristics of patients based on TAS2R38 genotype*
| PAV/AVI or AVI/AVI (n = 167) | PAV/PAV (n = 40) | p | |
|---|---|---|---|
| Gender | |||
| Male, n (%) | 98 (59) | 22 (55) | 0.72 |
| Age | |||
| Age at surgery (years) | 49 ±13 | 51 ± 12 | 0.35 |
| Ethnicitya | |||
| White, n (%) | 151 (90) | 33 (83) | 0.17 |
| Hispanic, n (%) | 2 (1) | 0 (0) | |
| Asian, n (%) | 0 (0) | 1 (3) | |
| Black, n (%) | 14 (8) | 6 (15) | |
| Preoperative characteristics | |||
| Current or former smoker, n (%) | 59 (37) | 14 (37) | 1.00 |
| Polyps, n (%) | 112 (67) | 30 (75) | 0.45 |
| Asthma, n (%) | 90 (54) | 25 (63) | 0.38 |
| Allergies, n (%) | 26 (65) | 113 (67) | 0.85 |
| Aspirin sensitivity, n (%) | 21 (13) | 8 (20) | 0.22 |
| Diabetes, n (%) | 17 (10) | 2 (5) | 0.54 |
| Allergic fungal sinusitis, n (%) | 23 (14) | 11 (28) | 0.06 |
| Primary surgery, n (%) | 56 (34) | 6 (15) | 0.02 |
| Lund-Mackay score | 13 ± 6 | 14 ± 5 | 0.48 |
| Initial SNOT score | 42 ± 20 | 51 ± 22 | 0.01 |
| Taste sensitivityb | |||
| PTC | 5 ± 4 | 8 ± 3 | <0.0001 |
| Quinine | 4 ± 3 | 3 ± 2 | 0.23 |
| Denatonium | 5 ± 3 | 4 ± 3 | 0.90 |
| Sucrose | 6 ± 2 | 6 ± 2 | 0.41 |
Results are shown for all 207 patients used in the study. There were no significant differences in the baseline characteristics of the initial 123 patients used for the study when analyzed by genotype (data not shown; p = 0.21 for primary surgery; p = 0.17 for initial SNOT score). Plus-minus values are means ± SD. Values of p are for the overall comparisons.
Ethnicity is self-reported; p value is for white vs non-white.
For taste tests, participants rated the taste intensity of solutions of the bitter agonists PTC, quinine, and denatonium, as well as sucrose.
AVI = nonfunctional receptor haplotype containing alanine, valine and isoleucine; PAV = functional receptor haplotype containing proline, alanine, and valine; PTC = phenylthiocarbamide; SD = standard deviation; SNOT = Sino-Nasal Outcome Test.